Table 4.

Disease relapse: local-regional versus distant: impact of TN category and treatment

TN Category	Local-Regional Relapse
	RT plus 5-FU/MMC Arm				RT plus 5-FU/CDDP Arm
	TF/No. of Patients	3 y %‡	HR (95% CI)	P value†	TF/No. of Patients	3 y %	HR (95% CI)	P value†
Node Negative
T2N0	19/161	10	1.00		38/162	19	1.00
T3N0	11/51	22	1.98 (0.94-4.15)	.072	6/45	13	0.59 (.25-1.39)	.22
T4N0	5/15	27	3.23 (1.21-8.66)	.02	6/16	38	2.13 (0.90-5.04)	.087
Node Positive
T2N1-3	10/46	18	1.97 (0.92-4.24)	.083	16/53	28	1.42 (0.79-2.55)	.24
T3N1-3	8/21	38	4.09 (1.79-9.36)	.0009	12/25	49	2.85 (1.49-5.46)	.0016
T4N1-3	11/18	61	8.00 (3.79-16.91)	<.0001	4/7	57	3.06 (1.09-8.58)	.033
P value*	<.0001				.0032
TN Category	Distant Metastases
	RT plus 5-FU/MMC Arm				RT plus 5-FU/CDDP Arm
	TF/No. of Patients	3 y %‡	HR (95% CI)	P value†	TF/No. of Patients	3 y %	HR (95% CI)	P value†
Node Negative
T2N0	14/161	7	1.00		24/162	12	1.00
T3N0	8/51	14	1.91 (0.80-4.56)	.14	5/45	9	0.81 (0.31-2.12)	.66
T4N0	3/15	14	2.49 (0.72-8.67)	.15	4/16	19	2.04 (0.71-5.88)	.19
Node Positive
T2N1-3	11/46	19	3.00 (1.36-6.61)	.0064	17/53	26	2.57 (1.38-4.78)	.0029
T3N1-3	3/21	10	2.01 (0.58-7.02)	.27	8/25	33	2.91 (1.30-6.48)	.0091
T4N1-3	6/18	28	6.36 (2.43-16.63)	.0002	0/7	0	-	-
P value*	.015				.0093

Abbreviations: CDDP = cisplatin; CI = confidence interval; HR = hazard ratio; MMC = mitomycin; TF = total failures.

^*P value from the Gray’s test.

^†P value from χ² test using the Cox proportional hazards model.

^‡Some 3-year estimates might be unstable due to small sample sizes and, therefore, too few patients at risk at 3 years.